Repurposing Verapamil for Type 2 Diabetes: A Comprehensive Drug Discovery Process

Abstract

Type 2 Diabetes (T2D) is a chronic metabolic disorder characterized by insulin resistance and beta-cell dysfunction. Despite the availability of various therapeutic options, the search for more effective treatments with fewer side effects continues. This paper outlines a comprehensive drug discovery process for repurposing Verapamil as a novel T2D treatment, covering rationale, preclinical validation, ADMET and toxicology studies, and clinical trial design.

Introduction

T2D affects millions of people worldwide, posing significant health and economic burdens. The disease is characterized by insulin resistance and impaired insulin secretion, leading to hyperglycemia [1]. Current treatments for T2D include insulin sensitizers, secretagogues, and injectable therapies, each with its limitations [2].

Recent studies have revealed the critical role of calcium (Ca^{2+}) signaling in the functioning of pancreatic beta cells. These studies have implicated disruptions in Ca^{2+} homeostasis and its associated signaling pathways as key factors in the impairment of beta-cell function, which contributes to the onset and progression of diabetes [3].

Interestingly, the calcium channel blocker verapamil, a medication primarily used for its cardiovascular benefits, has demonstrated promising potential in preserving beta-cell function and improving insulin sensitivity in patients with type 1 diabetes [4-6]. These findings suggest that verapamil could be a viable candidate for repurposing as a treatment option for T2D.

By leveraging the existing knowledge about the importance of Ca^{2+} signaling in beta-cell function and the observed benefits of verapamil in type 1 diabetes, this paper aims to explore the potential of verapamil as a repurposed treatment for managing T2D.

Treatment Rationale

The proposed treatment approach combines the potential benefits of verapamil and exendin, leveraging their complementary mechanisms of action to address the key pathological features of T2D.

Verapamil, a calcium channel blocker, has demonstrated promising potential in the management of T2D. Its mechanism of action suggests it could address both major pathological hallmarks of the disease. By modulating calcium influx in pancreatic beta-cells, verapamil may enhance insulin secretion in response to glucose, thereby improving insulin sensitivity. Additionally, verapamil has been shown to inhibit the expression of thioredoxin-interacting protein (TXNIP), a pro-apoptotic protein. This

inhibition resulted in decreased beta-cell apoptosis and enhanced endogenous insulin levels, indicating verapamil's potential to preserve beta-cell function [5].

Exendin is a glucagon-like peptide-1 (GLP-1) receptor agonist, which can stimulate the GLP-1 receptor, leading to increased insulin secretion from pancreatic beta-cells in a glucose-dependent manner. Exendin also suppresses glucagon secretion, helping to maintain glycemic control [7].

By conjugating verapamil with peptides like exendin-4, which binds specifically to GLP-1 receptors (highly expressed on pancreatic beta-cells), the specificity of verapamil for the pancreas can be enhanced. This conjugation serves a dual purpose: it acts as a delivery system for verapamil and helps improve glycemic control. The combination of verapamil and exendin offers a comprehensive strategy for targeting insulin resistance early in the progression of T2D. By addressing both the preservation of beta-cell function and the enhancement of insulin sensitivity and secretion, the Verapamil-Exendin conjugate has the potential to provide a more effective management approach for this chronic condition.

Disease and Targets

T2D is characterized by a complex interplay between insulin resistance in peripheral tissues and beta-cell dysfunction in the pancreas. In T2D, cells in the muscle, fat, and liver become resistant to insulin, leading to elevated blood sugar levels, as they do not take up glucose from the bloodstream. The beta-cells in the pancreas may not produce enough insulin or may function poorly, contributing to the observed hyperglycemia [8]. Verapamil, a calcium channel blocker, has the potential to address these critical components of T2D pathogenesis. First, it targets the L-type calcium channels in pancreatic beta-cells, which play a crucial role in insulin secretion. By modulating these channels, verapamil can enhance insulin secretion in response to glucose, improving insulin sensitivity. Studies have shown that verapamil exerts anti-inflammatory effects, which may improve insulin sensitivity in peripheral tissues [9]. This multi-faceted approach targeting beta-cell function and insulin sensitivity makes verapamil a promising candidate for T2D management. At the molecular level, the Verapamil-Exendin conjugate targets two key pathways involved in T2D pathogenesis. Verapamil inhibits the expression of thioredoxin-interacting protein (TXNIP), a pro-apoptotic protein. This inhibition results in decreased beta-cell apoptosis and enhanced endogenous insulin levels, indicating verapamil’s potential to preserve beta-cell function [5]. Exendin stimulates the GLP-1 receptor, leading to increased insulin secretion in a glucose-dependent manner and improving insulin sensitivity in peripheral tissues [7].

Preclinical Validation

The preclinical validation of the Verapamil-Exendin conjugate will involve a comprehensive set of studies to elucidate the drug's mechanism of action and evaluate its efficacy in relevant in vitro and in vivo models of T2D.

Biochemical Studies

Initial studies will focus on investigating the effects of Verapamil on insulin secretion and action in isolated pancreatic islets and insulin-responsive cell lines. These biochemical studies aim to elucidate the drug's mechanism of action at the molecular level [10]. Assays like enzyme assays and immunoassays will be conducted to evaluate the impact of the Verapamil-Exendin conjugate on insulin secretion, beta-cell viability, and GLP-1 receptor activation.

Animal Studies

Rodent models of T2D will be utilized to assess the efficacy of the Verapamil-Exendin conjugate in improving glycemic control, insulin sensitivity, and beta-cell preservation. Both genetically modified and diet-induced obesity models will be considered to cover a broad spectrum of T2D pathologies. The db/db mouse, which carries a mutation in the leptin receptor gene, will be used as it closely mimics the progression of human T2D, exhibiting obesity, insulin resistance, and eventual beta-cell dysfunction. Additionally, the Goto-Kakizaki (GK) rat, a nonobese, nonhypertensive model of T2D, will be employed as it shares a susceptibility locus on chromosome 10 and develops adult-onset T2D early in life [11]. These animal studies will evaluate the impact of the Verapamil-Exendin conjugate on glycemic control, lipid profiles, and organ histology, providing valuable insights into the in vivo efficacy of the treatment.

Organoid Studies

To further validate the drug's effects in a human-relevant system, pancreatic organoids derived from human stem cells will be employed. These organoids mimic the structure and function of pancreatic islets, allowing for the study of Verapamil's effects on human beta-cell function and survival in a controlled environment [12]. Throughout these preclinical studies, various bioinformatics tools and techniques will be utilized to analyze the data, including gene expression analysis, pathway analysis, and statistical analysis using R and Python libraries

ADMET and Toxicology Studies

The pharmacokinetics and safety profile of the Verapamil-Exendin conjugate in the context of T2D will be evaluated through comprehensive ADMET studies. These studies will assess the absorption, distribution, metabolism, and excretion of the drug candidate to understand its pharmacokinetic behavior. To ensure the safety and efficacy of the combination therapy, the potential drug-drug interactions, particularly with common T2D medications will be assessed. Long-term toxicity evaluations will be a crucial component of the ADMET studies. Safety pharmacology assessments will examine the impact of the Verapamil-Exendin conjugate on cardiovascular, hepatic, renal, and hematological parameters to ensure its safety profile [13]. For the ADMET and toxicology studies, various computational tools and modeling approaches will be employed. NONMEM (Nonlinear Mixed

Effects Modeling) will be used for pharmacokinetic/pharmacodynamic (PK/PD) modeling, which is used in drug development. Simcyp Simulator or GastroPlus will simulate and predict the ADME of the drug candidate in humans and animals [14]. The ToxRTool will assess the reliability of the toxicology data generated during the studies [15].

Clinical Trials

The clinical development of the Verapamil-Exendin conjugate for the treatment of T2D will follow the standard phases of clinical trials [16].

Phase I

Initial Phase I trials will assess the safety and tolerability of the Verapamil-Exendin conjugate in a small group of healthy volunteers and T2D patients. These studies will focus on identifying any adverse effects and determining the optimal dosing regimen. Since Verapamil is an existing drug with well-established safety profiles, the Phase I trials may emphasize pharmacokinetic assessments related to the interaction between Verapamil and Exendin, and potential dosing adjustments for the new indication.

Phase II

A larger cohort of T2D patients will be recruited for Phase II trials to evaluate the efficacy of the Verapamil-Exendin conjugate in improving glycemic control, compared to a placebo or standard care. This phase will also continue to monitor the safety and side effects of the combination therapy.

Phase III

Multi-center, randomized Phase III trials will compare the effectiveness and safety of the Verapamil-Exendin conjugate against current standard care treatments in a diverse T2D population. The primary endpoints will include HbA1c levels, fasting glucose, insulin sensitivity indices, and beta-cell function markers.

Phase IV

Post-marketing Phase IV studies will monitor the long-term safety and effectiveness of the Verapamil-Exendin conjugate in the general T2D population, with a focus on cardiovascular outcomes and beta-cell preservation.

Patient Population Selection

The selection of patients for the clinical trials of the Verapamil-Exendin conjugate will be based on a set of carefully considered inclusion and exclusion criteria to ensure the generalizability of the trial results.

Inclusion Criteria

The target patient population will include adults diagnosed with T2D, particularly those with evidence of insulin resistance and inadequate glycemic control on their current medications. This will allow for the evaluation of the Verapamil-Exendin conjugate's efficacy in a population that could potentially benefit the most from the treatment.

Exclusion Criteria

Patients with type 1 diabetes, significant renal or hepatic impairment, or a history of adverse reactions to similar compounds will be excluded from the trials. These exclusions will help minimize the risk of adverse events and ensure the safety of the study participants.

Stratification

To better understand the treatment's efficacy and safety profile across different subgroups, patients may be stratified based on various characteristics, such as:

1. Body Mass Index (BMI)
2. Duration of diabetes
3. Baseline HbA1c levels
4. Presence of comorbidities (e.g., cardiovascular disease, hypertension)
5. C-peptide levels
6. Previous treatment response

This stratification approach, as suggested by the reference "Population stratification in type 2 diabetes mellitus: A systematic review" by Hodgson et al., [17] will help assess the Verapamil-Exendin conjugate's efficacy and safety in specific subgroups of the T2D population. This, in turn, will help identify any potential predictors of treatment response and guide the development of more personalized treatment approaches.

REFERENCES

1. Zheng, Y., Ley, S. H., & Hu, F. B. (2018). Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. *Nature reviews endocrinology*, *14*(2), 88-98.

2. Padhi, S., Nayak, A. K., & Behera, A. (2020). Type II diabetes mellitus: a review on recent drug based therapeutics. *Biomedicine & Pharmacotherapy*, *131*, 110708.

3. Abdul Mu-u-min, R. B., Diane, A., Allouch, A., & Al-Siddiqi, H. H. (2023). Ca^{2+}-Mediated Signaling Pathways: A Promising Target for the Successful Generation of Mature and Functional Stem Cell-Derived Pancreatic Beta Cells In Vitro. *Biomedicines*, *11*(6).

4. Zimmermann, P., Aberer, F., Eckstein, M. L., Haupt, S., Erlmann, M. P., & Moser, O. (2022). Verapamil and Its Role in Diabetes. *diabetology*, *3*(3), 393-406.

5. Arefanian, H., Koti, L., Sindhu, S., Ahmad, R., Al Madhoun, A., & Al-Mulla, F. (2023). Verapamil chronicles: advances from cardiovascular to pancreatic β-cell protection. *Frontiers in Pharmacology*, *14*, 1322148.

6. Ajmal, N., Bogart, M. C., Khan, P., Max-Harry, I. M., & Nunemaker, C. S. (2023). Emerging anti-diabetic drugs for Beta-cell protection in type 1 diabetes. *Cells*, *12*(11), 1472.

7. Arakawa, M., Ebato, C., Mita, T., Hirose, T., Kawamori, R., Fujitani, Y., & Watada, H. (2009). Effects of exendin-4 on glucose tolerance, insulin secretion, and beta-cell proliferation depend on treatment dose, treatment duration and meal contents. *Biochemical and biophysical research communications*, *390*(3), 809-814.

8. Galicia-Garcia, U., Benito-Vicente, A., Jebari, S., Larrea-Sebal, A., Siddiqi, H., Uribe, K. B., ... & Martín, C. (2020). Pathophysiology of type 2 diabetes mellitus. *International journal of molecular sciences*, *21*(17), 6275.

9. Carnovale, C., Dassano, A., Mosini, G., Mazhar, F., D'Addio, F., Pozzi, M., ... & Clementi, E. (2020). The β-cell effect of verapamil-based treatment in patients with type 2 diabetes: a systematic review. *Acta Diabetologica*, *57*, 117-131.

10. Deore, A. B., Dhumane, J. R., Wagh, R., & Sonawane, R. (2019). The stages of drug discovery and development process. *Asian Journal of Pharmaceutical Research and Development*, *7*(6), 62-67.

11. Singh, R., Gholipourmalekabadi, M., & Shafikhani, S. H. (2024). Animal models for type 1 and type 2 diabetes: advantages and limitations. *Frontiers in Endocrinology*, *15*, 1359685.

12. Beydag-Tasöz, B. S., Yennek, S., & Grapin-Botton, A. (2023). Towards a better understanding of diabetes mellitus using organoid models. *Nature Reviews Endocrinology*, *19*(4), 232-248.

13. Pantaleão, S. Q., Fernandes, P. O., Gonçalves, J. E., Maltarollo, V. G., & Honorio, K. M. (2022). Recent advances in the prediction of pharmacokinetics properties in drug design studies: a review. *ChemMedChem*, *17*(1), e202100542.

14. Wu, F., Zhou, Y., Li, L., Shen, X., Chen, G., Wang, X., ... & Huang, Z. (2020). Computational approaches in preclinical studies on drug discovery and development. *Frontiers in chemistry*, *8*, 726.

15. Schneider, K., Schwarz, M., Burkholder, I., Kopp-Schneider, A., Edler, L., Kinsner-Ovaskainen, A., ... & Hoffmann, S. (2009). “ToxRTool”, a new tool to assess the reliability of toxicological data. *Toxicology letters*, *189*(2), 138-144.

16. Mahan, V. L. (2014). Clinical trial phases. *International Journal of Clinical Medicine*, *5*(21), 1374.

17. Hodgson, S., Cheema, S., Rana, Z., Olaniyan, D., O’Leary, E., Price, H., & Dambha-Miller, H. (2022). Population stratification in type 2 diabetes mellitus: A systematic review. *Diabetic Medicine*, *39*(1), e14688.